Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy
Abstract Background HER2 expression has been confirmed to be associated with bladder cancer aggressiveness. Anti-HER2 RC48-ADC is approved in China for the treatment of patients with advanced urothelial carcinoma with failed chemotherapy who are HER2 positive (IHC 2 + or 3 +). The discovery of HER2...
Saved in:
Main Authors: | Yatong Chen, Fei Luo, Tingji Zhang, Jian Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Biological Procedures Online |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12575-025-00261-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer
by: A. V. Troianov, et al.
Published: (2023-03-01) -
Nucleotide variation in Foxp3 gene and prognosis of bladder cancer: a case-control study
by: Qin Li, et al.
Published: (2025-01-01) -
Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment
by: Liam Mannion, et al.
Published: (2024-11-01) -
Prognostic evaluation of non-muscle invasive bladder cancer with P-CRP and its nomogram
by: Junyun Wu, et al.
Published: (2025-02-01) -
Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study
by: Takashi Kawahara, et al.
Published: (2025-01-01)